Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Clinical Sarcoma Research

Fig. 1

From: Cytotoxic and targeted therapy for treatment of pseudomyogenic hemangioendothelioma

Fig. 1

Imaging studies for 45-year-old patient (“Case 1”) with pseudomyogenic hemangioendothelioma. a Baseline fat saturated T1-weighted axial magnetic resonance image with intravenous contrast enhancement of the pelvis demonstrates multiple enhancing tumor foci in the right iliac bone (white arrow). b Positron emission tomography-computed tomography (PET-CT) fusion image through the pelvis demonstrates diffuse metabolic activity in the right anterior iliac bone (disease in the right posterior iliac bone at the level of the sacroiliac joint was also present but is not shown). This image was obtained 1 month before the patient began gemcitabine/docetaxel. c PET-CT fusion image through the pelvis after three cycles of gemcitabine/docetaxel demonstrates a significant metabolic response

Back to article page